Drug intelligence / Profile preview

TNK03

Development stage: Preclinical
Lead developer: SynoCare
Modality: Small Molecules

Overview

TNK03 is a preclinical-stage small molecule therapeutic being developed by SynoCare for the treatment of solid tumors. The drug utilizes a synthetic lethality strategy, a precision medicine approach that exploits specific genetic vulnerabilities in cancer cells to selectively induce cell death while sparing healthy tissue. While the exact molecular target (designated as TNK03XX in pipeline documentation) remains undisclosed by the sponsor, the program is a key component of SynoCare's oncology pipeline focused on novel mechanisms of action and precision oncology.

Beyond the preview

Go deeper on TNK03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNK03.

Explore the full profile